
Opinion|Videos|January 20, 2025
Patient Selection for Teplizumab and Infusion Process
Panelists discuss how patient selection for teplizumab therapy requires careful screening for autoantibody positivity and preserved C-peptide function, followed by a 14-day outpatient infusion process that needs close monitoring for cytokine release syndrome and other potential adverse effects.
Advertisement
Episodes in this series

Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
Survey Finds Most PCPs Do Not Use uACR to Assess Cardiovascular Risk in Type 2 Diabetes
2
COVID-19 Vaccination Linked to Lower Risk of Severe Outcomes in Pregnancy Across Delta and Omicron Periods
3
Digital Screening Tool Duo Shows Promise for ADRD Detection in Primary Care: Daily Dose
4
FDA Accepts Supplemental Application for Teplizumab to Delay Stage 3 Type 1 Diabetes in Children Aged 1 Year and Older
5




























































































































































































































































































































